Samsung Bioepis Partners with Teva Pharmaceutical for Blood Disease Drug Biosimilar EPYSQLI in the US

MT Newswires Live

2025/01/14

Samsung Biologics (KRX:207940) subsidiary Samsung Bioepis and Israel's Teva Pharmaceutical entered into a licensing, development, and commercialization agreement for EPYSQLI, or eculizumab-aagh, biosimilar to Soliris in the US.

Samsung Bioepis will handle the development, regulatory registration, manufacturing, and supply, while Teva Pharmaceutical will manage the product's commercialization.

EPYSQLI is a complement inhibitor used to treat rare diseases such as paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, Samsung Bioepis said Friday.

Financial details of the deal were undisclosed.

Shares of Samsung Biologics rose more than 1% in recent trade on Tuesday.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2503595566"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2503595566\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2503595566?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-14 11:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2503595566","market":"fut","top_or_hot":-1,"title":"Samsung Bioepis Partners with Teva Pharmaceutical for Blood Disease Drug Biosimilar EPYSQLI in the US","media":"MT Newswires Live","content":"<html><body><p> Samsung Biologics (KRX:207940) subsidiary Samsung Bioepis and Israel's Teva Pharmaceutical entered into a licensing, development, and commercialization agreement for EPYSQLI, or eculizumab-aagh, biosimilar to Soliris in the US.</p><p>Samsung Bioepis will handle the development, regulatory registration, manufacturing, and supply, while Teva Pharmaceutical will manage the product's commercialization.</p><p>EPYSQLI is a complement inhibitor used to treat rare diseases such as paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, Samsung Bioepis said Friday.</p><p>Financial details of the deal were undisclosed.</p><p>Shares of Samsung Biologics rose more than 1% in recent trade on Tuesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Samsung Bioepis Partners with Teva Pharmaceutical for Blood Disease Drug Biosimilar EPYSQLI in the US</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSamsung Bioepis Partners with Teva Pharmaceutical for Blood Disease Drug Biosimilar EPYSQLI in the US\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-01-14 11:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Samsung Biologics (KRX:207940) subsidiary Samsung Bioepis and Israel's Teva Pharmaceutical entered into a licensing, development, and commercialization agreement for EPYSQLI, or eculizumab-aagh, biosimilar to Soliris in the US.</p><p>Samsung Bioepis will handle the development, regulatory registration, manufacturing, and supply, while Teva Pharmaceutical will manage the product's commercialization.</p><p>EPYSQLI is a complement inhibitor used to treat rare diseases such as paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, Samsung Bioepis said Friday.</p><p>Financial details of the deal were undisclosed.</p><p>Shares of Samsung Biologics rose more than 1% in recent trade on Tuesday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4584","symbol_name":"避孕概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2503595566","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503595566","pubTimestamp":1736825630,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Samsung Biologics (KRX:207940) subsidiary Samsung Bioepis and Israel's Teva Pharmaceutical entered into a licensing, development, and commercialization agreement for EPYSQLI, or eculizumab-aagh, biosi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4584":"避孕概念","BK4559":"巴菲特持仓","BK4596":"哈里斯概念","BK4007":"制药","BK4566":"资本集团","BK4585":"ETF&股票定投概念","BK4588":"碎股","BK4557":"大麻股","TEVA":"梯瓦制药"},"translate_title":"三星Bioepis与梯瓦制药在美国合作开发血液病药物生物类似药EPYSQLI","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEVA":1},"content_text":"Samsung Biologics (KRX:207940) subsidiary Samsung Bioepis and Israel's Teva Pharmaceutical entered into a licensing, development, and commercialization agreement for EPYSQLI, or eculizumab-aagh, biosimilar to Soliris in the US.Samsung Bioepis will handle the development, regulatory registration, manufacturing, and supply, while Teva Pharmaceutical will manage the product's commercialization.EPYSQLI is a complement inhibitor used to treat rare diseases such as paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, Samsung Bioepis said Friday.Financial details of the deal were undisclosed.Shares of Samsung Biologics rose more than 1% in recent trade on Tuesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}